Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt

NCT04310319 is registered in ClinicalTrials.gov with Esther Meijer as lead sponsor.

NCT NCT04310319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04310319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt
Lead sponsor
Esther Meijer
Phase
Not applicable
Overall status
Unknown status
Start date
September 7, 2020
Completion date
October 31, 2021
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adpkd, autosomal dominant polycystic kidney, polycystic kidney, autosomal dominant